ReviewInternational journal of nephrology and renovascular disease2016
Dialysis-related amyloidosis: challenges and solutions.
Review in International journal of nephrology and renovascular disease, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
66 citing papers in PubMed, 1 synthesis or guideline pooled it, 133 citations in OpenAlex.
- Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach From the Writing Committee of the American Society for Apheresis: The Tenth Special Issue.Journal of clinical apheresis · 2026Guideline
- Comparison of Landmark-Based Versus Transverse Carpal Ligament Penetrating Corticosteroid Injection for Bilateral Carpal Tunnel Syndrome: A Prospective Randomized Trial.Clinics in orthopedic surgery · 2025Trial
- Targeting Uremic Toxins in Chronic Kidney Disease: Current Challenges and Emerging Therapeutic Strategies.Toxins · 2026Review
- Dialysis-related amyloidosis mimicking metastatic bone disease: a scintigraphic pitfall of non-MDP-avid osteolytic lesions on bone SPECT/CT.EJNMMI research · 2026Article
- Bilateral Amyloid Arthropathy of the Hip Joint Presented with Pathologic Fracture in a Hemodialysis Patient: A Case Report.Hip & pelvis · 2026Article
- A case of effective tocilizumab for arthropathy due to dialysis-related amyloidosis.CEN case reports · 2025Article
- Clinical outcomes of posterior lumbar interbody fusion in chronic renal failure patients on hemodialysis.Nagoya journal of medical science · 2025Article
- A Rare Case Report of Wunderlich Syndrome in a Chronic Hemodialysis Patient.Reports (MDPI) · 2025Article
- High risk of postoperative complications in dialysis patients undergoing total hip arthroplasty: a database study of Japanese nationwide medical claims.Scientific reports · 2025Article
- The effect of pre-transplant dialysis duration on the relationship between delayed graft function and recipient death.Scientific reports · 2025Article
- Imaging Findings in Amyloid Arthropathy of the Hip Joints: The Eyes Cannot See What the Mind Does Not Know.The Indian journal of radiology & imaging · 2025Article
- Affibodies as valuable tool to prevent βBiology direct · 2025Article
- Hydrophobic Interactions in Aqueous Osmolyte Solutions: Thermodynamics of Solvation and Implication on Protein Stability.The journal of physical chemistry. B · 2025Article
- Guide to the structural characterization of protein aggregates and amyloid fibrils by CD spectroscopy.Protein science : a publication of the Protein Society · 2025Article
- Bio-sociological and clinical factors of chronic pain and pain interference in patients undergoing hemodialysis: a cross-sectional study.BMC nephrology · 2025Article
- Amyloids and the Heart: An Update.Journal of clinical medicine · 2024Review
- Elevated concentration of beta2-microglobulin among patients with carpal tunnel syndrome in the course of primary Sjögren syndrome - a prospective observational study on 50 patients.Rheumatology international · 2024Observational
- Article
- Carpal tunnel release in the dialysis-dependent population: Incidence and outcomes.Journal of hand and microsurgery · 2024Article
- A review of recent clinical trials to evaluate disease-modifying therapies in the treatment of cardiac amyloidosis.Frontiers in medicine · 2024Review
6 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Amyloidosis refers to the extracellular tissue deposition of fibrils composed of low-molecular-weight subunits of a variety of proteins. These deposits may result in a wide range of clinical manifestations depending upon their type, location, and the amount of deposition. Dialysis-related amyloidosis is a serious complication of long-term dialysis therapy and is characterized by the deposition of amyloid fibrils, principally composed of β2 microglobulins (β2M), in the osteoarticular structures and viscera. Most of the β2M is eliminated through glomerular filtration and subsequent reabsorption and catabolism by the proximal tubules. As a consequence, the serum levels of β2M are inversely related to the glomerular filtration rate; therefore, in end-stage renal disease patients, β2M levels increase up to 60-fold. Serum levels of β2M are also elevated in several pathological conditions such as chronic inflammation, liver disease, and above all, in renal dysfunction. Retention of amyloidogenic protein has been attributed to several factors including type of dialysis membrane, prolonged uremic state and/or decreased diuresis, advanced glycation end products, elevated levels of cytokines and dialysate. Dialysis treatment per se has been considered to be an inflammatory stimulus, inducing cytokine production (such as interleukin-1, tumor necrosis factor-α, interleukin-6) and complement activation. The released cytokines are thought to stimulate the synthesis and release of β2M by the macrophages and/or augment the expression of human leukocyte antigens (class I), increasing β2M expression. Residual renal function is probably the best determinant of β2M levels. Therefore, it has to be maintained as long as possible. In this article, we will focus our attention on the etiology of dialysis-related amyloidosis, its prevention, therapy, and future solutions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.